AI News about protagonist therapeutics

Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights

Protagonist Lands FDA Win, Threatens Immunology Giants Protagonist Therapeutics received its first FDA approval, securing a $50 million immediate payment from its Johnson & Johnson partnership. The breakthrough positions the biotech company to challenge established players in the immunology sector. Industry analysts suggest the approval could reshape competitive dynamics among major pharmaceutical immunology programs.